Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.02 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 04/20/15 All times are local (Market data is delayed by at least 15 minutes).

ligand pharmaceuticals-tr rt (LGNZZ) Snapshot

Open
$0.02
Previous Close
$0.02
Day High
$0.02
Day Low
$0.02
52 Week High
09/26/14 - $0.03
52 Week Low
04/30/14 - $0.0060
Market Cap
--
Average Volume 10 Days
3.5K
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for LIGAND PHARMACEUTICALS-TR RT (LGNZZ)

ligand pharmaceuticals-tr rt (LGNZZ) Related Businessweek News

View More BusinessWeek News

ligand pharmaceuticals-tr rt (LGNZZ) Details

Ligand Pharmaceuticals Incorporated operates as a biotechnology company in the United States. The company’s commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis that is used for the treatment of multiple myeloma; bazedoxifene, which is used for the treatment of postmenopausal osteoporosis; and Captisol-enabled Noxafil-IV, a formulation of posaconazole for intravenous (IV) use. Its late-stage development programs include Captisol-enabled Melphalan IV, MK-8931 Beta-Secretase Inhibitor, Captisol-enabled SAGE-547, Sparsentan, Captisol-enabled Delafloxacin-IV, Captisol-enabled Carbamazepine-IV, IRAK4 Inhibitor Program, LTP Technology with Omega-3 Fatty Acids, Biologic Therapeutics Platform, Captisol-enabled Topiramate IV, Lasofoxifene, and Captisol-enabled Lamotrigine IV. The company’s internal product development programs include Glucagon Receptor Antagonist Program, Oral Human Granulocyte Colony Stimulating Factor Program, LTP Platform, Kinase Inhibitors, HepDirect HCV Inhibitor Program, and other programs. Its therapies in development portfolio addresses the unmet medical needs of patients for a range of diseases, including hepatitis, multiple myeloma, muscle wasting, Alzheimer’s disease, dyslipidemia, diabetes, anemia, epilepsy, focal segmental glomerulosclerosis, and osteoporosis. Ligand Pharmaceuticals Incorporated has alliances with GlaxoSmithKline, Amgen, Inc., Merck, Pfizer, Baxter International, and Eli Lilly and Co. The company was founded in 1987 and is headquartered in La Jolla, California.

19 Employees
Last Reported Date: 02/23/15
Founded in 1987

ligand pharmaceuticals-tr rt (LGNZZ) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: $510.2K
President and Chief Operating Officer
Total Annual Compensation: $375.4K
Chief Financial Officer and Vice President of...
Total Annual Compensation: $300.5K
Vice President, General Counsel and Secretary
Total Annual Compensation: $288.9K
Compensation as of Fiscal Year 2014.

ligand pharmaceuticals-tr rt (LGNZZ) Key Developments

Ligand Pharmaceuticals Incorporated Announces Management Changes

Ligand Pharmaceuticals Incorporated announced the appointment of Melanie J. Herman as interim Chief Financial Officer, effective May 21, 2015. Ms. Herman currently serves as Ligand’s Director of Accounting and Chief Accounting Officer. She succeeds Nishan de Silva, who has accepted the position of President and Chief Operating Officer at a privately held therapeutics-focused gene editing company and who has notified Ligand of his resignation, to be effective next month. Ms. Herman joined Ligand in January 2011 as the company’s Controller, and was named Director of Accounting in March 2014 and Chief Accounting Officer in April 2014. Previously she was Controller at CyDex Pharmaceuticals Inc. from 2009 to 2011, Assistant Controller and Accounting Manager at Entertainment Properties Trust from 2004 to 2009 and Senior Accountant at KPMG, LLP from 2001 to 2004.

Ligand Pharmaceuticals Incorporated Presents at 2015 Deutsche Bank Pharma OneonOne Day, Mar-26-2015

Ligand Pharmaceuticals Incorporated Presents at 2015 Deutsche Bank Pharma OneonOne Day, Mar-26-2015 . Venue: JW Marriott Denver at Cherry Creek, 150 Clayton Lane, Denver, CO 80206, United States.

Ligand Pharmaceuticals Incorporated, Annual General Meeting, Apr 24, 2015

Ligand Pharmaceuticals Incorporated, Annual General Meeting, Apr 24, 2015., at 08:30 Pacific Daylight. Location: 11119 North Torrey Pines Road. Agenda: To elect a board of directors for the forthcoming year; to ratify the selection of Grant Thornton LLP as the company's independent registered accounting firm for the fiscal year ending December 31, 2015; to consider and vote upon, on an advisory basis, the compensation of its named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission; and to transact such other business as may properly come before the meeting or any adjournment(s) thereof.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LGNZZ:US $0.02 USD 0.00

LGNZZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LGNZZ.
View Industry Companies
 

Industry Analysis

LGNZZ

Industry Average

Valuation LGNZZ Industry Range
Price/Earnings 100.0x
Price/Sales 27.6x
Price/Book 66.8x
Price/Cash Flow 146.6x
TEV/Sales 21.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LIGAND PHARMACEUTICALS-TR RT, please visit www.ligand.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.